Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology 2 Q 2 0 2 6 F I N AN C I AL R E S U LT S C AL L J U LY 2 3 , 2 0 2 6 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: VISION 2030 is our Engine for Long-term Growth
VISION 2030 is our Engine for Long-term Growth 50k patients on 10labeled 5 late-stage treatment indications molecules Build diversified Scale VYVGART Expand across immunology portfolio in in MG and CIDP indications and assets FcRn and beyond 3
Slide 4: VYVGART Has the Broadest Label Across all gMG
VYVGART Has the Broadest Label Across all gMG Now Approved VYVGART is the First and Only Targeted Treatment Approved for Adults with gMG across all Serotypes Anti-AChR antibody positive Anti-MuSK antibody positive Anti-LRP4 antibody positive Triple seronegative Mary Beth, MG Patient 4
Slide 5: Autoimmune Myositis is a Quintessential argenx Opportunity
Autoimmune Myositis is a Quintessential argenx Opportunity Zero approved or Clear Biology IMNM late-development therapies Breakthrough Therapy Designation for IMNM High Unmet Need A Multi-blockbuster DM Heterogeneous disease; Opportunity Limited treatments U.S. Prevalence 5
Slide 6: A Pivotal Year for Empasiprubart
A Pivotal Year for Empasiprubart Sustained Grip Strength Improvement in Phase 2 ARDA OLE 12k patients across MMN ARDA Phase 2 ARDA+ Open Label key markets Grip strength change from baseline (kPA) UNMET NEED 40% Initially 0 Targeted 60% Progression misdiagnosed treatments despite treatment DISEASE BU
Slide 7: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline IIP/Preclinical Phase 1 PoC Registrational Approved ARGX-118 (Galectin) AMR Ocular MG gMG1 – CIDP – ITP (Japan) ARGX-124 (FcRn) Scleroderma ITP 25 ARGX-125 AIE Graves’ Disease Active IIP TSP-101 (Fn14) DGF* Sjogren’s Disease programs PROGRAMS SMA Myos
Slide 8: Product Net Sales of $1.5 Billion in Q2
Product Net Sales of $1.5 Billion in Q2 Product Net Sales by Quarter 1.516 Quarter over Quarter (QoQ) growth: 2Q26 vs 1Q26 $’m (in millions of $) Q2 2026 Q1 2026 Growth Growth % * China 1.286 1.298 US 1,273 1,107 166 15% RoW Japan 1) 102 67 35 55% Japan 1.127 Rest of the World 136 112 24 22% US 949
Slide 9: Q2 2026 Financial Summary
Q2 2026 Financial Summary Three months ended Six months ended June 30 June 30 Operating (in million of $) 2026 2025 2026 2025 profit of $0.5B Product net sales Other operating income $ 1,516 26 949 19 2,813 41 1,739 36 +146% YoY Total operating income $ 1,542 967 2,854 1,775 Cost of sales $ (145) (1
Slide 10: Patient-first Commercial Execution
Patient-first Commercial Execution More HCPs choosing VYVGART More patients Patients staying as #1 biologic in MG & CIDP requesting VYVGART on VYVGART Jai, VYVGART Patient 10
Slide 11: VYVGART Growth Momentum Continues Across MG and CIDP
VYVGART Growth Momentum Continues Across MG and CIDP Increasing Breadth & Seronegative gMG Label PFS Driving Demand Depth of Prescription Expansion ~80% of PFS patients >5,000 neurologists First and only new to VYVGART biologic approved across in 2Q/26 Earlier-line use all gMG serotypes Internal arg
Slide 12: Strong Early Momentum Following gMG Label Expansion
Strong Early Momentum Following gMG Label Expansion PATIENTS PHYSICIANS PAYERS +11k >80% ~55% Patients now Of seronegative MG U.S. commercial eligible in U.S. treaters covered lives covered “I honestly sat at my Significant Halo effect on Most plans remove unmet need gMG patients serology testing co
Slide 13: Evidence Generation Supports CIDP Market Expansion
Evidence Generation Supports CIDP Market Expansion CIDP Market CIDP Evidence Generation Expansion Opportunity +18K Diagnosed, Not Treated Improved grip strength 1 42K +12K For up to 96 weeks Total Diagnosed Patients Successful IVIG switch study 2 Diagnosed, ‘Well-Managed’ on Treatment 87.5% response
Slide 14: Augmenting our Commercialization Engine to Prepare for Successful Entry into Rheumatology
Augmenting our Commercialization Engine to Prepare for Successful Entry into Rheumatology Best-in-Class Partnerships with Patients Patient Engagement AIM Patient Program Advocacy Groups Payors Strong Market Access Capabilities Proactive Payor Engagements Expanded MSL Disease Medical Sales Field Expa
Slide 15: Innovation Has No Value Unless it Provides Meaningful Benefit to Patients
Innovation Has No Value Unless it Provides Meaningful Benefit to Patients 15
Slide 16: Alternative Performance Measure Statement
Alternative Performance Measure Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for th